Organon Valuation
Is OGN * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of OGN * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: OGN * (MX$299) is trading below our estimate of fair value (MX$1115.93)
Significantly Below Fair Value: OGN * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for OGN *?
Other financial metrics that can be useful for relative valuation.
What is OGN *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$4.77b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 2.1x |
Enterprise Value/EBITDA | 8.3x |
PEG Ratio | 1.2x |
Price to Earnings Ratio vs Peers
How does OGN *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 46x | ||
LAB B Genomma Lab Internacional. de | 14.5x | 26.7% | Mex$15.2b |
500660 GlaxoSmithKline Pharmaceuticals | 67.6x | 21.1% | ₹357.8b |
000513 Livzon Pharmaceutical Group | 18.4x | 9.8% | CN¥31.7b |
4581 Taisho Pharmaceutical Holdings | 83.5x | 18.2% | JP¥703.3b |
OGN * Organon | 4.7x | 3.8% | Mex$4.8b |
Price-To-Earnings vs Peers: OGN * is good value based on its Price-To-Earnings Ratio (4.7x) compared to the peer average (46.1x).
Price to Earnings Ratio vs Industry
How does OGN *'s PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?
Price-To-Earnings vs Industry: OGN * is good value based on its Price-To-Earnings Ratio (4.7x) compared to the Global Pharmaceuticals industry average (24.5x).
Price to Earnings Ratio vs Fair Ratio
What is OGN *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 4.7x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate OGN *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | n/a | Mex$364.72 0% | 21.6% | Mex$474.99 | Mex$254.46 | n/a | 8 |
Apr ’25 | Mex$279.00 | Mex$363.77 +30.4% | 22.2% | Mex$476.52 | Mex$255.28 | n/a | 8 |
Mar ’25 | n/a | Mex$365.90 0% | 22.2% | Mex$479.30 | Mex$256.77 | n/a | 8 |
Feb ’25 | n/a | Mex$348.19 0% | 27.0% | Mex$459.84 | Mex$204.37 | n/a | 9 |
Jan ’25 | n/a | Mex$349.54 0% | 28.0% | Mex$464.14 | Mex$189.10 | n/a | 9 |
Dec ’24 | Mex$195.00 | Mex$349.54 +79.3% | 28.0% | Mex$464.14 | Mex$189.10 | n/a | 9 |
Nov ’24 | n/a | Mex$506.88 0% | 25.5% | Mex$787.79 | Mex$348.10 | n/a | 9 |
Oct ’24 | n/a | Mex$501.74 0% | 20.6% | Mex$741.11 | Mex$396.41 | n/a | 9 |
Sep ’24 | n/a | Mex$497.46 0% | 21.7% | Mex$731.31 | Mex$391.17 | n/a | 8 |
Aug ’24 | Mex$364.67 | Mex$475.12 +30.3% | 23.6% | Mex$720.01 | Mex$351.63 | n/a | 8 |
Jul ’24 | n/a | Mex$516.03 0% | 22.0% | Mex$747.95 | Mex$365.28 | n/a | 9 |
Jun ’24 | n/a | Mex$547.21 0% | 18.7% | Mex$764.51 | Mex$408.92 | n/a | 9 |
May ’24 | Mex$424.00 | Mex$569.36 +34.3% | 17.1% | Mex$773.14 | Mex$431.52 | n/a | 9 |
Apr ’24 | Mex$380.00 | Mex$624.12 +64.2% | 15.2% | Mex$815.71 | Mex$455.28 | Mex$279.00 | 10 |
Mar ’24 | Mex$450.00 | Mex$603.71 +34.2% | 16.0% | Mex$789.30 | Mex$440.54 | n/a | 9 |
Feb ’24 | n/a | Mex$631.36 0% | 17.5% | Mex$814.46 | Mex$454.58 | n/a | 9 |
Jan ’24 | n/a | Mex$654.38 0% | 17.5% | Mex$844.15 | Mex$471.15 | n/a | 9 |
Dec ’23 | n/a | Mex$621.47 0% | 15.6% | Mex$735.13 | Mex$464.29 | Mex$195.00 | 8 |
Nov ’23 | Mex$500.00 | Mex$688.03 +37.6% | 15.7% | Mex$817.66 | Mex$498.57 | n/a | 8 |
Oct ’23 | Mex$481.00 | Mex$747.59 +55.4% | 6.0% | Mex$820.10 | Mex$680.09 | n/a | 8 |
Sep ’23 | n/a | Mex$749.18 0% | 4.9% | Mex$813.68 | Mex$694.60 | n/a | 8 |
Aug ’23 | n/a | Mex$777.12 0% | 6.5% | Mex$835.33 | Mex$692.71 | Mex$364.67 | 7 |
Jul ’23 | Mex$690.00 | Mex$766.48 +11.1% | 6.7% | Mex$861.59 | Mex$685.35 | n/a | 7 |
Jun ’23 | Mex$750.00 | Mex$790.97 +5.5% | 7.9% | Mex$892.63 | Mex$694.27 | n/a | 8 |
May ’23 | n/a | Mex$816.10 0% | 7.9% | Mex$918.11 | Mex$714.08 | Mex$424.00 | 8 |
Apr ’23 | n/a | Mex$824.27 0% | 7.3% | Mex$913.03 | Mex$750.72 | Mex$380.00 | 8 |
Analyst Forecast: Target price is less than 20% higher than the current share price.